Although <i>STAG2</i> deficiency comprises only a small subset of gliomas, this case adds clinical evidence to existing preclinical data supporting a role for <i>STAG2</i> mutations in gliomagenesis and resistance to standard therapies. The gene discussed is STAG2; the disease is central nervous system cancer.